Cardiogen Peptide Therapy
Benefits, Side Effects, Cost & Protocols
Cardiogen (Ala-Glu-Asp-Arg) is a short bioregulatory peptide targeting cardiac tissue. It is studied for its potential to normalize myocardial function, support cardiovascular health, and promote heart tissue repair.
Clinically Reviewed
Reviewed by Alex Evans, PharmD, MBA · Updated May 2026
Evidence-Based
Sourced from FDA, PubMed & ClinicalTrials.gov · View sources
Who Is Cardiogen Best For?
How Cardiogen Works
Bioregulator peptide that may interact with gene promoter regions in cardiomyocytes, modulating expression of proteins involved in cardiac contractility and tissue maintenance.
Cardiogen FAQ
What is CARDIOGEN?
Cardiogen is a Khavinson bioregulator tripeptide (Ala-Glu-Asp) researched for cardiovascular tissue support and cardiac cell function in age-related decline.
How does CARDIOGEN work?
Bioregulator peptide that may interact with gene promoter regions in cardiomyocytes, modulating expression of proteins involved in cardiac contractility and tissue maintenance.
Is CARDIOGEN legal to buy?
CARDIOGEN is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.
Where can I buy CARDIOGEN?
CARDIOGEN is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.
What category does CARDIOGEN belong to?
CARDIOGEN is primarily classified as a tissue repair & healing peptide. Peptides studied for their potential in wound healing, tendon/ligament repair, gut healing, and general tissue regeneration.
What are the research benefits of CARDIOGEN?
CARDIOGEN has been studied for: Cardiac tissue support, Cardiovascular function, Myocardial health, Age-related heart support. Khavinson bioregulator; cardiovascular/cardiac tissue focus.
Key Studies
77 total on PubMed58 human trials[Worsening in patients treated in acute stroke units--results of the Austrian Stroke Unit Registry]
Ferrari J, Flamm-Horak A, Lischka-Lindner A et al
Wien Med Wochenschr · Wien Med Wochenschr
Diabetes, hypertension, cardioembolism, and large vessel disease predict early clinical worsening in stroke patients
[Cardiomyopathy and ion channel diseases registry: the Szeged CardioGen Registry]
Blazsó P, Kákonyi K, Forster T et al
Orv Hetil · Orv Hetil
Registry of 809 cardiomyopathy and ion channel disease patients with similar mortality/morbidity to literature
[Investigation of insertion/deletion polymorphism of the ACE gene in stroke patients]
Pongrácz E, Tordai A, Csornai M et al
Ideggyogy Sz · Ideggyogy Sz
ACE D/D polymorphism not independent stroke risk factor but associated with hyperlipidemia in young patients
2011 investigation of internal contamination with radioactive strontium following rubidium Rb 82 cardiac PET scan
Cardiogen Compound Data
Cardiogen News
Cardiogen Peptide: A Promising Tool for Regenerative and Molecular Research - Out South Florida
Out South Florida · 7 months ago
Cardiogen and the molecular language of cardiac renewal: A speculative exploration - Dawn
Dawn · 2 months ago
Cardiogen Peptide: Unveiling Its Research Potential in Cardiac Investigations - Рубрика
Рубрика · 8 months ago
Cardiogen Peptide: A gateway to innovative implications in biological research - Times of Malta
Times of Malta · 16 months ago
Cartalax Peptide: Unveiling Potential Pathways in Cellular Aging and Tissue Integrity - NR Times
NR Times · 12 months ago
News aggregated via Google News. Inclusion does not imply endorsement.
Ready to explore Cardiogen with a provider?
Take our 2-minute quiz to get matched with a board-certified provider specializing in Cardiogen.
Take the Quiz →